McKesson Corporation (MCK)
| Market Cap | 120.94B |
| Revenue (ttm) | 397.96B |
| Net Income (ttm) | 4.34B |
| Shares Out | 122.49M |
| EPS (ttm) | 34.74 |
| PE Ratio | 28.42 |
| Forward PE | 22.83 |
| Dividend | $3.28 (0.34%) |
| Ex-Dividend Date | Mar 2, 2026 |
| Volume | 1,059,841 |
| Open | 977.28 |
| Previous Close | 974.45 |
| Day's Range | 974.00 - 987.37 |
| 52-Week Range | 619.48 - 987.37 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 930.23 (-5.79%) |
| Earnings Date | Feb 4, 2026 |
About MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialt... [Read more]
Financial Performance
In fiscal year 2025, McKesson's revenue was $359.05 billion, an increase of 16.22% compared to the previous year's $308.95 billion. Earnings were $3.30 billion, an increase of 9.76%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for MCK stock is "Strong Buy." The 12-month stock price target is $930.23, which is a decrease of -5.79% from the latest price.
News
See How Institutional Inflows Make McKesson Fly
McKesson Corporation (MCK) shares up 58% in a year thanks to Big Money.
McKesson Corporation: Strong Q3 Earnings But Upside Exhausted
McKesson Corporation shares are now fairly valued after a 16% price increase, prompting a Hold rating. Strong Q3 results were driven by 11% revenue growth and a 37% surge in the Oncology & Multispecia...
Allspring Large Cap Growth Fund Q4 2025 Performance Update
The Allspring Large Cap Growth Fund underperformed the Russell 1000 Growth Index during the fourth quarter. As VYVGART gains traction with new patients, argenx continues to advance its pipeline, targe...
How McKesson Stock Surged 17% In A Day
McKesson (MCK), a prominent pharmaceutical wholesaler, experienced a stock increase of 17% during a high-volume trading session. The driver for this surge was a strong Q3 earnings report that surpasse...
Trump Ally Mullin Buys 10 Stocks, Including These $5 Billion Companies You've Probably Never Heard Of
Mullin reported the purchase of 10 stocks in a new disclosure, according to the Benzinga Government Trades page. The stock purchases were all made on Jan. 5, 2026, with Mullin reporting two purchases ...
McKesson Corporation (MCK) Q3 2026 Earnings Call Transcript
McKesson Corporation (MCK) Q3 2026 Earnings Call Transcript
McKesson boosts 2026 profit forecast amid specialty drug growth
McKesson Corporation raised its fiscal 2026 profit forecast on Wednesday, betting on strong growth in its oncology and specialty drug distribution businesses.
McKesson Corporation Reports Fiscal 2026 Third Quarter Results and Raises Full Year Adjusted EPS Guidance
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2026 third quarter financial results. Results can be accessed on McKesson's Investor Relations website at inves...
McKesson Corporation Completes Divestiture of Norwegian Operations
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it has closed the transaction to sell its retail and distribution businesses in Norway to NorgesGruppen, a private...
McKesson Corporation Declares Quarterly Dividend
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE: MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on ...
McKesson's Practice Insights Designated as a 2026 Qualified Clinical Data Registry by Centers for Medicare & Medicaid Services
IRVING, Texas--(BUSINESS WIRE)--For the tenth year, CMS named McKesson a Qualified Clinical Data Registry approved to participate in the Merit-based Incentive Payment System.
McKesson Corporation (MCK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
McKesson Corporation (MCK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #AI--Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. T...
Final Trades: Lockheed Martin, QXO and McKesson Corporation
CNBC's “Halftime Report” Investment Committee discuss their top stocks to watch for the second half of the day's trading session.
McKesson Corporation: FY26 Earnings Visibility Underpins Buy Case
McKesson Corporation is undervalued despite strong revenue growth, margin expansion, and capital returns; I rate it Buy with a $920 target (13.5% upside). MCK's strategy focuses on boosting margins by...
Mckesson Corporation Announces Third Quarter Fiscal 2026 Earnings Release Date
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2026 financial results after market close on Wednesday, February 4, 2026. The company will host a...
Our Top 10 High-Growth Dividend Stocks - December 2025
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
McKesson Corporation (MCK) Presents at Evercore 8th Annual Healthcare Conference Transcript
McKesson Corporation (MCK) Presents at Evercore 8th Annual Healthcare Conference Transcript
McKesson's Advancing Community Oncology Report Charts a New Era of Innovation for Biopharma and Community Care
IRVING, Texas--(BUSINESS WIRE)--McKesson published its first-ever Advancing Community Oncology Report, a look at the trends influencing community oncology practices across the U.S.
Final Trades: Freeport-McMoRan, Cisco, Teradyne and McKesson Corp.
The Investment Committee give you their top stocks to watch for the second half.
Our Top 10 High Growth Dividend Stocks - November 2025
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
McKesson Corporation (MCK) Presents at UBS Global Healthcare Conference 2025 Transcript
McKesson Corporation ( MCK) UBS Global Healthcare Conference 2025 November 10, 2025 9:30 AM EST Company Participants Britt Vitalone - Executive VP & CFO Conference Call Participants Kevin Caliendo - ...
McKesson Corporation (MCK) Q2 2026 Earnings Call Transcript
McKesson Corporation ( MCK) Q2 2026 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jeni Dominguez - Head of Investor Relations Brian Tyler - CEO & Director Britt Vitalone - Executive...
McKesson raises annual profit forecast on robust demand for specialty drugs
Drug distributor McKesson raised its fiscal 2026 profit forecast on Wednesday, betting on strong growth in its oncology and specialty drug distribution businesses.
McKesson Corporation Reports Fiscal 2026 Second Quarter Results and Raises Full Year Adjusted EPS Guidance
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2026 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at inve...